Fig. 7

Model showing the mechanism through which CDKL1 is involved in immune evasion in lung cancer. (A) The absence of CDKL1 facilitates YBX1 binding to the PD-L1 promoter, thereby upregulating the expression of PD-L1. This, in turn, leads to the inactivation of CD8⁺ T cells and subsequent immune evasion, ultimately conferring resistance to radioimmunotherapy. (B) CDKL1 binds to YBX1 and suppresses the accumulation of YBX1 on the PD-L1 promoter, consequently downregulating the expression of PD-L1. This reduction in PD-L1 expression promotes the activation of CD8⁺ T cells, ultimately sensitizing lung cancer to radioimmunotherapy